Bimodal distribution and set point HBV DNA viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa

Louise O Downs[1,2], Sabeehah Vawda[3], Phillip Armand Bester[3], Katrina A Lythgoe[4,5], Tingyan Wang[2], Anna L McNaughton[2], David A Smith[2,6,9], Tongai Maponga[7], Oliver Freeman[6,11], Kinga A Várnai[6,9], Jim Davies[6,10], Kerrie Woods[6,9], Christophe Fraser[4], Eleanor Barnes[2,6,8], Dominique Goedhals[3], Philippa C Matthews[1,2,6]

[1] Department of Infectious Diseases and Microbiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK;
[2] Nuffield Department of Medicine, Medawar Building for Pathogen Research, University of Oxford, Oxford, UK;
[3] Division of Virology, University of the Free State and National Health Laboratory Service, Bloemfontein, South Africa;
[4] Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, University of Oxford, United Kingdom
[5] Department of Zoology, University of Oxford, M Medawar Building for Pathogen Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK
[6] National Institute of Health Research Health Informatics Collaborative, NIHR Oxford Biomedical Research Centre, Oxford, UK;
[7] Department of Virology, University of Stellenbosch, Tygerberg Hospital, Cape Town, South Africa
[8] Department of Hepatology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK;
[9] Oxford University Hospitals NHS Foundation Trust, Oxford, UK;
[10] Department of Computer Science, University of Oxford, Oxford, UK;
[11] Nuffield Department of Population Health, University of Oxford, Oxford, UK.

CONFLICT OF INTEREST: Nil

CORRESPONDING AUTHOR

Professor Philippa C Matthews:

Email: philippa.matthews@ndm.ox.ac.uk

Address: Medawar Building for Pathogen Research, South Parks Road, Oxford OX1 3SY, UK

Telephone: 0044 1865 271973

AUTHORS' CONTRIBUTIONS

- Study concept and design: PCM, ALM.
- Development of the health informatics (HIC) pipeline: DS, JD, OF, KV, KW
- Acquisition and interpretation of South African data: SV, PAB, TM, DG, LOD
- Acquisition and interpretation of UK data: LOD, DAS, ALM
- Analysis of the data: TW, CF, KAL
- Literature review: LOD, PCM
- Wrote the manuscript: LOD, PCM
- Critical revision of manuscript: LOD, PCM, ALM, KAL, CF
- Edited and approved the final manuscript: All authors

FUNDING

PCM is funded by the Wellcome Trust (ref 110110). KAL is funded by the Wellcome Trust and the The Royal Society (ref 107652/Z/15/Z). LOD is funded by the NIHR.

Introduction

Hepatitis B virus (HBV) DNA viral loads (VL) show wide variation between individuals with chronic hepatitis B (CHB) infection, and are used to determine treatment eligibility (1). There are few refined descriptions of VL distribution in CHB, and limited understanding of the biology that underpins these patterns. We set out to describe the VL distribution in independent cohorts from the UK and South Africa, to identify associated host characteristics, and to compare with VL in HIV-1 and hepatitis C (HCV) infection.

Methods

We retrospectively collected baseline and longitudinal HBV VL measurements, HBeAg status and demographic data from treatment-naïve adults with CHB between 2011-2016 from electronic records at a UK teaching hospital (n=351), as described previously (2). We also analysed all HBV VL data from the South African National Health Laboratory Service (NHLS), representing a four-year period from 1st January 2015 (n=6506). We used longitudinal data from the UK HBeAg-negative cohort, and from South African patients with detectable viraemia to investigate the relative contributions of within- and between-host variation to VL variability. A large contribution of between-host variation would provide support for a set-point viral load (SPVL), as is observed for HIV. We compared HBV VLs with pre-treatment HCV VLs from the same UK cohort (n=925) and HIV SPVLs from a previous European study (n=1581) (3). More details of clinical cohorts and statistical analysis are presented in Suppl. methods.

Results

In the UK cohort, overall median HBV VL was 3.4 $\log_{10}$ IU/mL; 95% CI 3.2 – 3.5 $\log_{10}$ IU/mL (equivalent to median 4·2 $\log_{10}$ copies/ml). There was a bimodal VL distribution (Fig 1A) with peaks as follows:

- HBeAg-negative infection (accounting for 304/351 (87%) of measurements): median VL 3·2 $\log_{10}$ IU/mL (95% CI 3·0 – 3·4); right-skewed distribution (Fig 1A).
- HBeAg-positive infection (accounting for 47/351 (13%) of measurements): median VL 7·6 $\log_{10}$ IU/mL (95% CI 5·6 – 8·2); left-skewed distribution (Fig 1B)

In the South African dataset (HBeAg status not determined), median HBV VL was 4·6 $\log_{10}$ IU/mL (95% CI 3·9 – 4·0), with a bimodal distribution and right-skew (Fig 1C).

For the UK data we investigated whether sex, age or ethnicity had any influence on VL; the only significant association was lower VL with increasing age in the HBeAg-positive group (p=0·01 by Kruskal Wallis, Suppl. Fig 1).

Longitudinal data were available for 299 patients in the UK cohort and 874 patients in the South African cohort. Inter-patient variation accounted for 82·7% and 88·0% of the variability in UK and South African datasets respectively, whilst within-patient variation accounted for 17·3% and 12·0%. This provides support for a stable SPVL within individuals with CHB.

Median HIV VL was 4·5 $\log_{10}$ copies/mL and median HCV VL was 6·0 $\log_{10}$ IU/ml (6·4 $\log_{10}$ copies/ml), with a left skew and no bimodal distribution (Fig 1D,E), and significantly different viraemia compared to HBV (p<0·0001; Fig 1F).

Discussion

HBV VL distribution in our diverse UK population is in keeping with a large South African dataset, as well as other previously published studies (e.g. (4–6)). Although the bimodal distribution of HBV VL is consistent between cohorts, descriptions of this pattern have not previously been carefully refined. The relationship between HBeAg status and VL is in keeping with the role of HBeAg in immunomodulation (7).

HBV viral loads in HBeAg-negative infection are significantly lower than HCV and HIV, which may relate to differences in viral population structure, viral fitness, influence of host immune responses, and the availability of target cells. These factors might also explain why HIV, HCV and HBeAg-positive infection have left skew VL distributions, whereas HBeAg-negative infection has a right skew. This is the first study to explore the concept of SPVL in HBV infection, with between-host factors explaining over 80% of the variation in VL measurements during HBeAg-negative CHB.

Our data represent a small but well-defined UK cohort, and a much larger South African population without the benefit of relevant supporting metadata; long-term aspirations will be to investigate larger VL datasets together with robust clinical and laboratory parameters.

Next generation sequencing (NGS) has the potential to increase our understanding of HBV but approximately 50% of cases fall below the current sequencing threshold of ~3 $\log_{10}$ IU/mL (8). Enhanced descriptions of HBV VL may shed light on the biology of chronic HBV infection, improve understanding of risk factors for transmission and disease progression at a population level, inform optimisation of viral sequencing methods, and help to stratify patients for clinical trials and treatment.

Metadata

The metadata underpinning this analysis are available on-line:
https://figshare.com/s/cd8b046346250dd349b0
On acceptance of this manuscript for publication, the data will be made available through a permanent DOI: 10.6084/m9.figshare.11365082

147 **Figure 1: Distribution of viral loads for adults with chronic infection with HBV,**
148 **HIV and HCV**
149



150
151

152 # References

153

154 1. Lampertico P, Agarwal K, Berg T et al. EASL 2017 Clinical Practice Guidelines on the
155 management of hepatitis B virus infection. *J Hepatol.* 2017;**67(2)**:370–98.
156 2. Downs LO, Smith DA, Lumley SF et al. Electronic Health Informatics Data To Describe
157 Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in
158 Chronic Hepatitis B Virus Infection. *MBio*. 2019. **25;10**(3).
159 3. Blanquart F, Wymant C, Cornelissen M et al. Viral genetic variation accounts for a third of
160 variability in HIV-1 set-point viral load in Europe. *PLoS Biol.* 2017. **15(6)**:e2001855.
161 4. Pyne MT, Vest L, Clement J et al. Comparison of three roche hepatitis B virus viral load assay
162 formats. *J Clin Microbiol.* 2012; **50(7)**:2337–42.
163 5. Meldal BHM, Bon AH, Prati D, Ayob Y, Allain JP. Diversity of hepatitis B virus infecting
164 Malaysian candidate blood donors is driven by viral and host factors. *J Viral Hepat.* 2011;
165 **18(2)**:91–101.
166 6. Allain JP, Candotti D, Soldan K et al. The risk of hepatitis B virus infection by transfusion in
167 Kumasi, Ghana. *Blood.* 2003. **101(6)**:2419–25.
168 7. Milich D, Liang TJ. Exploring the Biological Basis of Hepatitis B e Antigen in Hepatitis B Virus
169 Infection. *Hepatology.* 2003. **38:**1075–86.
170 8. McNaughton AL, D'Arienzo V, Ansari MA et al. Insights From Deep Sequencing of the HBV
171 Genome—Unique, Tiny, and Misunderstood. *Gastroenterology.* 2019;**156(2)**:384–99.

172